These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37355363)

  • 21. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
    Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
    Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
    Sande CM; Chang B; Monga V; Bossler AD; Ma D
    Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
    Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
    Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.
    Molina-Vila MA; Bertran-Alamillo J; Gascó A; Mayo-de-las-Casas C; Sánchez-Ronco M; Pujantell-Pastor L; Bonanno L; Favaretto AG; Cardona AF; Vergnenègre A; Majem M; Massuti B; Morán T; Carcereny E; Viteri S; Rosell R
    Clin Cancer Res; 2014 Sep; 20(17):4647-59. PubMed ID: 24696321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
    Kajiwara T; Nishina T; Yamashita R; Nakamura Y; Shiozawa M; Yuki S; Taniguchi H; Hara H; Ohta T; Esaki T; Shinozaki E; Takashima A; Yamamoto Y; Yamazaki K; Yoshino T; Hyodo I
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 mutations in advanced colorectal cancer: the dark side of the moon.
    Pietrantonio F; Biondani P; Perrone F; Di Bartolomeo M; Pacifici M; Milione M; Melotti F; Maggi C; Montemurro G; Bossi I; Mariani L; de Braud F
    Oncology; 2014; 86(5-6):289-94. PubMed ID: 24924261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
    Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
    Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
    De Bruijn MT; Raats DA; Tol J; Hinrichs J; Teerenstra S; Punt CJ; Rinkes IH; Kranenburg O
    Anticancer Res; 2011 Apr; 31(4):1379-85. PubMed ID: 21508389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
    Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
    Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.